keyword
https://read.qxmd.com/read/38660093/prognostic-significance-vestibular-examination-results-in-patients-with-vestibular-migraine
#1
JOURNAL ARTICLE
Fumiyuki Goto, Koichiro Wasano, Shoji Kaneda, Kenji Okami
INTRODUCTION: Vestibular migraine (VM) is a newly defined clinical condition. Several vestibular abnormalities have been reported in patients with VM. However, to date, no specific vestibular examinations are used to define VM. Therefore, the utility of vestibular examinations is limited. Currently, the role of vestibular examination has not been clearly defined. We speculated that the results of vestibular examinations could predict the prognosis of VM. We investigated the relationship between the vestibular examination results and clinical outcomes in patients with VM...
2024: Frontiers in Neurology
https://read.qxmd.com/read/38641932/a-comparative-study-on-prophylactic-efficacy-of-cinnarizine-and-amitriptyline-in-childhood-migraine-a-randomized-double-blind-clinical-trial
#2
RANDOMIZED CONTROLLED TRIAL
Mehrnaz Olfat, Sareh Hosseinpour, Safdar Masoumi, Reena Gogia Rastogi, Eric Vance Hastriter, Kara Stuart Lewis, Robert Little, Kavitha T Karnik, Carolyn Hickman, Morteza Heidari, Reza Shervin Badv, Mahmoud Mohammadi, Gholam Reza Zamani, Masoud Mohammadpour, Mahmoud Reza Ashrafi, Ali Reza Tavasoli
BACKGROUND: Pediatric migraine prophylaxis is indicated when headaches are frequent and/or disabling. We aimed to conduct a study to compare the efficacy of cinnarizine and amitriptyline in pediatric migraine prophylaxis. METHODS: In a randomized, double-blind trial, patients aged 4-17 years with migraine who were eligible for prophylaxis enrolled. The primary outcome was a reduction response rate of ≥50% with p  < 0.005 with respect to headache characteristics...
April 2024: Cephalalgia: An International Journal of Headache
https://read.qxmd.com/read/38617722/topiramate-induced-ocular-complications-case-series
#3
Sarita Lobo, Geover Joslen Lobo
UNLABELLED: Several ocular adverse effects have been attributed to Topiramate, a sulfonamide derivative. It can cause problems in the eye such as choroidal effusion syndrome, acute angle closure glaucoma, myopic shift, visual field defects, and Myokymia. If not identified early, it can be vision-threatening. It is commonly used for migraine prophylaxis, partial onset, and generalized tonic-clonic seizures. It has also been prescribed for bipolar disorder and alcoholism. The risk of adverse reactions with this drug is 3%...
2024: Romanian Journal of Ophthalmology
https://read.qxmd.com/read/38617394/efficacy-of-probiotics-in-prevention-of-migraine-attacks-in-children-a-randomized-clinical-trial-study
#4
JOURNAL ARTICLE
Hassan Bazmamoum, Bentolhoda Keshtkarsohi, Younes Mohammadi, Afshin Fayyazi
OBJECTIVES: Migraine is a chronic and joint disease in children. The results of previous studies on the effectiveness of probiotics in preventing migraine attacks in children have been controversial. This study aims to investigate the effect of probiotics on migraine prophylaxis in children. MATERIALS & METHODS: In this clinical trial study, 41 children aged 5 to 15 with migraine enrolled the study in two control and intervention groups. Children in the intervention group (18 children) received propranolol at a dose of 1 mg per kilogram of body weight daily in two divided doses along with a 250 mg Yomogi capsule daily for three months, and children in the control group (23 children), received propranolol along with placebo for three months...
2024: Iranian Journal of Child Neurology
https://read.qxmd.com/read/38610729/reporting-quality-and-risk-of-bias-analysis-of-published-rcts-assessing-anti-cgrp-monoclonal-antibodies-in-migraine-prophylaxis-a-systematic-review
#5
REVIEW
Dimitrios Rikos, Michail Vikelis, Emmanouil V Dermitzakis, Panagiotis Soldatos, Dimitrios Rallis, Jobst Rudolf, Anna P Andreou, Andreas A Argyriou
Objective: Phase II/III randomized clinical trials (RCTs) are vulnerable to many types of bias beyond randomization. Insights into the reporting quality of RCTs involving migraine patients treated with monoclonal antibodies targeting the calcitonin gene-related peptide system (anti-CGRP MAbs) are currently lacking. Our aim was to analyze the reporting quality of phase II/III RCTs involving migraine patients treated with anti-CGRP MAbs. Methods: A systematic search was performed on the PubMed and EMBASE databases, according to PRISMA guidelines, for relevant RCTs in either episodic or chronic migraine prevention...
March 28, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38605779/comparison-of-the-efficacy-of-propranolol-versus-amitriptyline-as-monotherapy-for-prophylaxis-of-migraine
#6
JOURNAL ARTICLE
Krinaben M Patel, Kachhadia M Popatbhai, Roshni Xavier, Mohammed A S Aramin, Khalid J F Faris, Mohammed A Mateen, Priyadarshi Prajwal, Mohammed D M Marsool, Hafsa Sheikh, Esra H A G Mohamed
BACKGROUND: Approximately 15% of migraine sufferers need preventative medicine because they have more than two episodes each month. Migraine is a regular, persistent condition that frequently makes victims helpless. Numerous drugs from various classes have so far been used in migraine prophylaxis. Their effectiveness is recurrently overshadowed by their side effects because they must be used for a long time, which occasionally necessitates stopping the drug. MATERIALS AND METHODS: In the tertiary care teaching hospital's department of medicine, a prospective, comparative, open-label study was initiated...
February 2024: Journal of Family Medicine and Primary Care
https://read.qxmd.com/read/38602109/can-calcitonin-gene-related-peptide-monoclonal-antibodies-ameliorate-writer-s-cramp-and-migraine
#7
Keisuke Suzuki, Shiho Suzuki, Hiroaki Fujita, Hirotaka Sakuramoto, Mukuto Shioda, Koichi Hirata
Recently, calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) have become available as a prophylactic treatment for migraine and have shown high efficacy and safety in clinical practice. CGRP mAbs have been reported to be effective not only for migraine but also for other comorbidities, such as psychiatric complications in patients with migraine. However, there are no reports examining the effect of CGRP mAbs on dystonia. We treated a patient with comorbid migraine and focal task-specific dystonia (writer's cramp) with a CGRP mAb (erenumab) because of an increase in monthly migraine days despite the addition of migraine prophylaxis...
April 11, 2024: Neuropsychopharmacology Reports
https://read.qxmd.com/read/38591064/research-hotspots-and-trends-on-acupuncture-treatment-for-headache-a-bibliometric-analysis-from-2003-to-2023
#8
JOURNAL ARTICLE
Shun Zhao, Songfeng Hu, Yujing Luo, Wangjun Li, Fenfen Zhao, Changkang Wang, Fanlei Meng, Xingwei He
BACKGROUND: While acupuncture treatment has gained extensive usage in addressing headaches, there remains a notable gap in the literature analysis for this field. Therefore, this study aims to conduct a literature review using Citespace, VOSviewer, and Bibliometrix, aiming to examine the current status, strengths, and potential future directions in the utilization of acupuncture for headache treatment. METHODS: Relevant literature on acupuncture treatment for headaches between 2003 and 2023 was retrieved from the Web of Science (WoS) core database...
2024: Frontiers in Neuroscience
https://read.qxmd.com/read/38540290/beyond-pain-relief-unveiling-the-multifaceted-impact-of-anti-cgrp-r-mabs-on-comorbid-symptoms-in-resistant-migraine-patients
#9
JOURNAL ARTICLE
Alessandra Della Vecchia, Ciro De Luca, Lucrezia Becattini, Letizia Curto, Elena Ferrari, Gabriele Siciliano, Sara Gori, Filippo Baldacci
The study aimed to evaluate the effects of monoclonal antibodies (mAbs) acting on the calcitonin gene-related peptide (CGRP) or its receptor (anti-CGRP/R mAbs) on migraine comorbidities of depression, anxiety, and fatigue in patients resistant to traditional therapies. The issue addressed in this study is pivotal to unveiling the role of this neurotransmitter beyond pain processing. We conducted an open-label prospective study assessing comorbidities in patients with high frequency (HFEM) and chronic migraine (CM), medication overuse headache (MOH), and resistance to traditional prophylaxis...
March 18, 2024: Biomedicines
https://read.qxmd.com/read/38520255/new-migraine-drugs-a-critical-appraisal-of-the-reason-why-the-majority-of-migraine-patients-do-not-receive-an-adequate-medication
#10
JOURNAL ARTICLE
Hans Christoph Diener, Arne May
The last three decades have produced several novel and efficient medications to treat migraine attacks and reduce attack frequency. Additionally, promising approaches for the development of acute therapy and migraine prophylaxis continue to be pursued. At the same time as we witness the development of better and more efficient medications with continuously fewer side effects, we also realise that the high cost of such therapies means that only a minority of migraine patients who could benefit from these medications can afford them...
March 2024: Cephalalgia: An International Journal of Headache
https://read.qxmd.com/read/38518628/addressing-limitations-of-single-gon-blockade-treatment-and-repetitive-intervention-with-gon-block-or-onabotulinum-toxin-a-in-chronic-migraine-part-2-of-three-men-in-a-boat-study
#11
JOURNAL ARTICLE
Mustafa Karaoğlan
This study investigated the effectiveness of three treatment interventions for managing migraine symptoms over a three-month assessment period: single greater occipital nerve block (GON), repetitive GON block, and single GON block combined with onabotulinium toxin A (BoNT-A) treatment. Significant improvements were observed across all treatment groups in various migraine-related parameters, including medication usage, frequency and severity of attacks, and subjective measures such as Headache Impact Test-6 scores and Pittsburgh Sleep Quality Index scores...
March 12, 2024: Clinical Neurology and Neurosurgery
https://read.qxmd.com/read/38518587/effects-of-prophylactic-drug-therapies-and-anti-calcitonin-peptide-related-monoclonal-antibodies-on-subjective-sleep-quality-an-italian-multicenter-study
#12
JOURNAL ARTICLE
Giovanna Viticchi, Vincenzo Di Stefano, Claudia Altamura, Lorenzo Falsetti, Angelo Torrente, Nicoletta Brunelli, Sergio Salvemini, Paolo Alonge, Marco Bartolini, Chiara Di Felice, Maria Stella Adragna, Gianluca Moroncini, Fabrizio Vernieri, Filippo Brighina, Mauro Silvestrini
OBJECTIVE/BACKGROUND: sleep alterations strongly influence migraine severity. Prophylactic therapies have a major impact on migraine frequency and associated symptoms. The study purpose was to compare the impact of oral drug therapies or gene-related anti-calcitonin monoclonal antibodies (anti-CGRP mAbs) on sleep alterations. We also evaluated which drug therapies are more effective on sleep quality and the different impact on migraine frequency and life quality. PATIENTS/METHODS: this is a multicenter, prospective study conducted in three specialized headache centers (Marche Polytechnic University, Ancona; University of Palermo, Palermo; Fondazione Policlinico Campus Bio-Medico, Rome)...
March 18, 2024: Sleep Medicine
https://read.qxmd.com/read/38506767/effects-of-transcranial-direct-current-stimulation-on-clinical-outcomes-calcitonin-gene-related-peptide-and-pituitary-adenylate-cyclase-activating-polypeptide-38-levels-in-menstrual-migraine
#13
JOURNAL ARTICLE
Buse Rahime Hasırcı Bayır, Serkan Aksu, Haşim Gezegen, Zerrin Karaaslan, Hande Yüceer, Tuba Cerrahoğlu Şirin, Cem İsmail Küçükali, Adnan Kurt, Sacit Karamürsel, Vuslat Yılmaz, Betül Baykan
OBJECTIVES: Transcranial direct current stimulation (tDCS) has been suggested as an alternative treatment option for migraine. The present study aimed to evaluate the efficacy of tDCS on clinical outcomes in addition to calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating peptide 38 (PACAP-38) levels in individuals with menstrual-related migraine (MRM) for the first time. MATERIALS AND METHODS: In this parallel study, 58 female patients between the ages of 18 and 45 years, including 36 with MRM and 22 with nonmenstrual migraines (nMM), were recruited...
March 19, 2024: Neuromodulation: Journal of the International Neuromodulation Society
https://read.qxmd.com/read/38505499/efficacy-of-acupuncture-related-therapy-for-migraine-a-systematic-review-and-network-meta-analysis
#14
REVIEW
Yinqin Liu, Yan Wang, Chuanhao Mi, Ziyue Wang, Yu Han, Xianghua Qi, Xiao Ding
OBJECTIVE: Migraine is a common neurological disorder, which resulting in significant societal and personal burdens. Acupuncture has attracted widespread attention in migraine prophylaxis and treatment in recent years. Although some studies have confirmed the effectiveness of acupuncture therapy in treating migraines, there is still a lack of comprehensive evaluation regarding the comparison between different types of migraines and various acupuncture therapies. Furthermore, certain special acupuncture methods have not received sufficient attention and research...
2024: Journal of Pain Research
https://read.qxmd.com/read/38500929/indian-consensus-on-the-role-of-amitriptyline-in-migraine-prophylaxis
#15
JOURNAL ARTICLE
Sumit Singh, A V Srinivasan, Tapas K Banerjee, Kanharam N Patel, Snehal S Muchhala, Bhavesh P Kotak
Migraine is a globally prevalent neurological disorder. Amitriptyline, a tricyclic antidepressant, has shown potential as a prophylactic treatment for migraine; however, its role as a first-line medication has been debated. A modified Delphi method was used to develop consensus statements on migraine and its management. The literature review identified knowledge gaps, and two survey rounds were conducted among a panel of experts. Consensus was reached for 12 out of 23 initial survey questions, whereas no consensus was reached for four questions after the deliberation in the second round...
February 2024: Curēus
https://read.qxmd.com/read/38435077/non-invasive-vagal-nerve-stimulation-pre-treatment-reduces-neurological-dysfunction-after-closed-head-injury-in-mice
#16
JOURNAL ARTICLE
Andreia Morais, Joon Yong Chung, Limin Wu, Cenk Ayata, Bruce Simon, Michael J Whalen
Non-invasive vagus nerve stimulation (nVNS) has recently been suggested as a potential therapy for traumatic brain injury (TBI). We previously demonstrated that nVNS inhibits cortical spreading depolarization, the electrophysiological event underlying migraine aura, and is relevant to TBI. Our past work also suggests a role for interleukin-1 beta (IL-1β) in cognitive deficits after closed head injury (CHI) in mice. We show that nVNS pre-treatment suppresses CHI-associated spatial learning and memory impairment and prevents IL-1β activation in injured neurons, but not endothelial cells...
2024: Neurotrauma reports
https://read.qxmd.com/read/38431293/efficacy-of-migraine-prophylaxis-treatments-for-treatment-na%C3%A3-ve-patients-and-those-with-prior-treatment-failure-a-protocol-for-systematic-review-and-network-meta-analysis-of-randomised-controlled-trials
#17
JOURNAL ARTICLE
Pawin Numthavaj, Thunyarat Anothaisintawee, John Attia, Gareth McKay, Ammarin Thakkinstian
INTRODUCTION: Migraine headache is a significant health problem affecting patients' psychological well-being and quality of life. Several network meta-analyses (NMAs) have compared the efficacy of migraine prophylaxis medications. However, some have focused exclusively on oral medications, while others were limited to injectable medications. Moreover, none of these NMAs conducted a stratified analysis between treatment-naïve patients and those with prior treatment failure. Therefore, this systematic review and NMA will compare the efficacy among all treatments for migraine prophylaxis, stratified by the treatment status of patients (ie, treatment-naïve and previous treatment failure)...
March 1, 2024: BMJ Open
https://read.qxmd.com/read/38420497/real-world-effectiveness-of-erenumab-in-japanese-patients-with-migraine
#18
JOURNAL ARTICLE
Keisuke Suzuki, Shiho Suzuki, Tomohiko Shiina, Yasuo Haruyama, Saro Kobayashi, Mukuto Shioda, Koichi Hirata
BACKGROUND: Real-world evidence of erenumab effectiveness in migraine patients in Asia with various comorbidities and multiple previous medication failures is still limited. METHODS: A 6-month single-center cohort study of 45 patients with episodic or chronic migraine (CM) treated with erenumab was conducted. In the cohort, 60.0% were switching from other calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs), and 66.7% had ≥4 prophylaxis failures...
February 29, 2024: Heliyon
https://read.qxmd.com/read/38405404/case-report-late-onset-type-3-hemiplegic-migraine-with-permanent-neurologic-sequelae-after-attacks
#19
Mantas Jokubaitis, Givi Lengvenis, Birutė Burnytė, Eglė Audronytė, Kristina Ryliškienė
This case study describes a 57-year-old woman with a six-year history of recurrent episodes characterized by visual, sensory, speech disturbances, hemiparesis and severe one-sided headaches accompanied by fever and altered consciousness. Initially misdiagnosed as a stroke, the atypical disease course and MRI findings led to additional genetic testing which revealed a sodium voltage-gated channel gene mutation (T1174S), confirming a diagnosis of sporadic hemiplegic migraine. The migraine prophylaxis showed some improvement in episode frequency and severity...
2024: Frontiers in Neurology
https://read.qxmd.com/read/38398444/anti-cgrp-and-anti-cgrp-receptor-monoclonal-antibodies-for-migraine-prophylaxis-retrospective-observational-study-on-209-patients
#20
JOURNAL ARTICLE
Vittorio Schweiger, Paola Bellamoli, Francesco Taus, Leonardo Gottin, Alvise Martini, Marta Nizzero, Eleonora Bonora, Giovanna Del Balzo, Katia Donadello, Erica Secchettin, Gabriele Finco, Daniele De Santis, Enrico Polati
BACKGROUND: Migraine is a neurological disorder characterized by attacks of head pain with prevalent unilateral localization, moderate to high intensity and specifically associated accompanying symptoms. METHODS: In this retrospective observational study, we analyzed data regarding 209 patients who had previously been diagnosed with migraine and who were prescribed, between 2019 and 2022, subcutaneous injections of anti-CGRP monoclonal antibodies (mAbs) fremanezumab or galcanezumab or anti-CGRP receptors mAb erenumab regardless of the concomitant assumption of any other acute-phase or prophylactic migraine medication...
February 17, 2024: Journal of Clinical Medicine
keyword
keyword
111314
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.